What Is GIP? Function, Effects and Research

GIP is a gut hormone that increases insulin release when blood glucose is high, and it is one of the two main incretin hormones.

Basics10 min read

Key takeaway

GIP stands for glucose-dependent insulinotropic polypeptide; its original name was gastric inhibitory polypeptide. It is a 42-amino-acid peptide hormone released by K cells in the small intestine. In healthy people it increases insulin when glucose is high and raises glucagon when glucose is low or normal. In type 2 diabetes its insulin effect is much weaker. Tirzepatide, an FDA-approved medicine, activates both the GIP and GLP-1 receptors.

At a glance

Article typeBasics
Main guideTirzepatide: complete guide
Regulatory statusFDA-approved“Tirzepatide is the first FDA-approved dual agonist” (Tirzepatide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited12 in this article · 40 across 18 articles on Tirzepatide
ProductTirzepatide product page

What is GIP is a question that often comes up because of tirzepatide, a medicine whose sequence is based on this hormone. GIP itself was sequenced in 1971. Human studies since then have measured how it shapes insulin and glucagon after a meal.

Quick answer: GIP is a natural incretin hormone made in the gut after eating. It helps the pancreas release more insulin, mainly when blood glucose is elevated. Native GIP is not an approved medicine. Tirzepatide is built on its sequence and acts on its receptor.

What does GIP stand for?

GIP has two names that share one set of initials. The original name was gastric inhibitory polypeptide. Early work found that it inhibited stomach acid secretion, so it was proposed as an "enterogastrone" (Meier et al., 2004b).

In 1971, John Brown and Jill Dryburgh published the full amino acid sequence of pig GIP. They described it as 43 amino acids long. Fifteen of its first 26 residues matched the positions in pig glucagon, and nine matched pig secretin (Brown and Dryburgh, 1971).

Later research showed that GIP stimulates insulin secretion in the presence of glucose (Takeda et al., 1987). The same initials are now read as glucose-dependent insulinotropic polypeptide. "Insulinotropic" means it stimulates insulin release. Both names still appear in the literature (Usdin et al., 1993), and FDA-approved labels use the newer one.

Is GIP a peptide?

Yes. GIP is a peptide hormone, a short chain of amino acids that carries a signal through the blood. Vitrapep's guide to what peptides are explains the general category.

Human GIP is 42 amino acids long. In 1987, a Kyoto University team isolated cDNA encoding human GIP from duodenal tissue. It showed that GIP is cut from a 153-residue precursor called preproGIP (Takeda et al., 1987). Table 1 summarizes key facts.

Table 1

Is GIP a peptide

FeatureWhat the research reportsSource
Length in humans42 amino acidsTakeda et al., 1987
Precursor153-residue preproGIPTakeda et al., 1987
Source cellK cell of the small intestineBuffa et al., 1975
Main release triggerDescribed as absorption of ingested fatMiyawaki et al., 2002
ReceptorGIP receptor, a G-protein-coupled receptor in the secretin and VIP familyUsdin et al., 1993
Intact half-life in bloodAbout 5.0 minutes in 10 healthy adultsMeier et al., 2004a
Approved medicine acting on its receptorTirzepatide (Mounjaro, Zepbound); first US approval 2022Mounjaro label

Where is GIP produced?

GIP is made by K cells in the lining of the small intestine. A 1975 study stained intestinal tissue from humans, pigs and dogs with antibodies against GIP. The reacting cells matched the K cell type, and the authors proposed calling them GIP cells (Buffa et al., 1975).

A 2002 paper described GIP as a duodenal hormone whose secretion is driven mainly by fat absorption. Mice fed a high-fat diet in that study secreted excess GIP (Miyawaki et al., 2002).

Once released, GIP lasts only minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) makes the first cut, and the kidneys handle final removal (Meier et al., 2004a).

How does GIP affect insulin and glucagon?

GIP acts through its own receptor. In 1993, a National Institute of Mental Health team cloned the rat GIP receptor. In cultured cells, activating it raised cyclic AMP and intracellular calcium (Usdin et al., 1993).

In the pancreas, GIP's action depends on the glucose level. A 2011 Danish study gave GIP or saline to 10 healthy young men in a randomized, double-blind design. Blood glucose was held low, normal or high (Christensen et al., 2011).

  • At high glucose, GIP more than doubled the insulin secretion rate. Glucagon fell by a similar amount with GIP and saline.
  • At normal glucose, GIP raised glucagon compared with saline.
  • At low glucose, GIP caused a larger early glucagon response, with little or no effect on insulin.

The authors described GIP as a "bifunctional blood glucose stabilizer." Glucagon signals the liver to release glucose, so raising it at low glucose works against a fall in blood sugar.

A 2019 study measured how much the body's own GIP matters after a meal. On four separate days, 18 healthy men received an experimental GIP receptor blocker, a GLP-1 receptor blocker, both, or saline. The order was randomized and double-blind (Gasbjerg et al., 2019).

Blocking the GIP receptor cut insulin secretion during glucose and meal tests by 30%. Blocking the GLP-1 receptor cut it by 8.6%, and blocking both cut it by 37%. The authors concluded that endogenous GIP affected post-meal glucose and insulin more than endogenous GLP-1.

Does GIP slow digestion or act outside the pancreas?

The old name suggests effects on the stomach, but human data point the other way. In a 2004 study, 15 healthy men received GIP or placebo on separate occasions around a solid test meal. The stomach's half-emptying time was 120 minutes in both conditions (Meier et al., 2004b).

GIP receptors are not limited to the pancreas. In rats, receptor messenger RNA appeared in the gut, fat tissue, heart, pituitary and adrenal cortex, and in several brain regions. It was not found in kidney, spleen or liver (Usdin et al., 1993). Finding a receptor's messenger RNA in a tissue does not prove the hormone has a meaningful effect there.

The Zepbound label is cautious about appetite. It says nonclinical studies "suggest the addition of GIP may further contribute to the regulation of food intake" (Zepbound label). Nonclinical means animal and laboratory work.

How is GIP different from GLP-1?

GIP and GLP-1 are both incretins, gut hormones that increase insulin release after eating. Vitrapep's article on what GLP-1 is covers the second hormone. Table 2 compares them using controlled human studies. C-peptide is released with insulin and is used to estimate insulin secretion.

Table 2

How is GIP different from GLP-1

MeasureGIPGLP-1Study and evidence level
Intact half-life in bloodAbout 5.0 minutesAbout 2.3 minutesMeier et al., 2004a; 10 healthy adults (human)
Drop in meal-related insulin secretion when its receptor is blocked30%8.6%Gasbjerg et al., 2019; 18 healthy men (human)
Insulin effect in mild type 2 diabetes vs. matched controlsMaximum effect 54% lowerReached 71% of the controls' C-peptide rise; difference not significantNauck et al., 1993; 9 patients and 9 controls (human)
GlucagonRaised at low and normal glucose; no change at high glucoseLowered during high-glucose clampsChristensen et al., 2011; Nauck et al., 1993 (human)
Gastric emptyingNo change with GIP compared with placeboBlocking its receptor sped up emptyingMeier et al., 2004b; Gasbjerg et al., 2019 (human)

In healthy men, GIP carried more of the meal-related insulin signal, but it did not slow the stomach. GLP-1 lowered glucagon in clamp studies.

What happens to GIP in type 2 diabetes?

The overall incretin effect is reduced in type 2 diabetes. A 1993 German study compared nine people with mild type 2 diabetes and nine age- and weight-matched controls. Each received synthetic human GIP, GLP-1 or placebo on separate days during hyperglycemic clamps (Nauck et al., 1993).

Both hormones increased insulin secretion in both groups. With GIP, the maximum effect in the diabetes group was 54% lower than in controls. GLP-1 kept most of its effect and also lowered glucagon, while GIP did not lower glucagon. The authors concluded that GLP-1, in contrast to GIP, retains much of its insulin-releasing activity in mild type 2 diabetes.

What do animal studies show about GIP and body weight?

Animal studies point in two directions. In a 2002 study, mice lacking the GIP receptor were protected from obesity and insulin resistance on a high-fat diet. They used fat as their preferred energy source (Miyawaki et al., 2002).

Other work activated the receptor instead. In Eli Lilly's 2018 report, tirzepatide (then LY3298176) reduced body weight and food intake in mice. Those effects were greater than with a GLP-1 receptor agonist (Coskun et al., 2018).

Both directions have reached human trials. Maridebart cafraglutide, an Amgen peptide-antibody conjugate, activates the GLP-1 receptor and blocks the GIP receptor. Its 52-week Phase 2 trial enrolled 592 participants (Jastreboff et al., 2025). In the obesity cohort of 465, mean body weight fell 12.3% to 16.2% across drug groups, versus 2.5% on placebo. Gastrointestinal adverse events were common, and no unexpected safety signals emerged.

These are different molecules in different studies, so their results cannot be compared directly. The studies cited here do not explain how both blocking and activating the GIP receptor can accompany lower body weight.

Tirzepatide is the FDA-approved medicine most directly tied to GIP. Its label states that tirzepatide "is based on the GIP sequence." It adds aminoisobutyric acid at positions 2 and 13 and a C20 fatty diacid at position 20. Its formula is C225H348N48O68 and its molecular weight is 4813.53 Da (Mounjaro label).

Lilly's 2018 paper describes a 39-amino-acid peptide. It binds the GIP receptor with an affinity comparable to native GIP. Its affinity for the GLP-1 receptor is about 5-fold weaker than native GLP-1 (Coskun et al., 2018).

The label says tirzepatide activates both receptors, "the targets for native GIP and GLP-1." It increases insulin secretion and reduces glucagon, both in a glucose-dependent manner. A two-receptor medicine cannot show by itself how much of its effect comes from the GIP side. Vitrapep's tirzepatide complete guide covers the trial program.

FDA first approved tirzepatide in 2022, as Mounjaro for type 2 diabetes (Mounjaro label). Zepbound is approved for weight reduction in adults with obesity, or overweight with a weight-related condition. It is also approved for moderate to severe obstructive sleep apnea in adults with obesity (Zepbound label).

Both labels carry a boxed warning about thyroid C-cell tumors in rats; human relevance is unknown. The Mounjaro label's most common adverse reactions include nausea, diarrhea, decreased appetite and vomiting. FDA's November 2026 eye-risk labeling action also lists Mounjaro and Zepbound (see FDA's GLP-1 eye-risk warning).

Retatrutide adds glucagon receptor activity to GIP and GLP-1 activity. It is investigational and not FDA-approved; see the retatrutide complete guide.

Is GIP itself an approved medicine?

No. A search of FDA's Drugs@FDA data finds no approved product containing native GIP. Vitrapep's list of FDA-approved peptide medicines shows which related molecules are approved.

The human GIP studies cited here are short physiology studies in small groups of volunteers. They were not designed to establish long-term safety, and their abstracts do not report adverse event rates. A study that does not report adverse events has not shown that none occurred.

A research-use-only label does not make a compound legal or safe for people; see research peptides and human-use risks. Vitrapep's guide on how to evaluate peptide research explains study designs like these.

Frequently asked questions

What does GIP stand for?

Glucose-dependent insulinotropic polypeptide. It was first named gastric inhibitory polypeptide because early work found it inhibited stomach acid secretion.

Is GIP a peptide?

Yes. Human GIP is a 42-amino-acid peptide hormone cut from a 153-residue precursor.

Is GIP the same as GLP-1?

No. Both are incretin hormones, but they act on different receptors. In human studies, GIP raised glucagon at low and normal glucose, while GLP-1 lowered glucagon.

Does GIP slow stomach emptying?

A 2004 study in 15 healthy men found no change in gastric emptying with GIP compared with placebo.

Does GIP still work in type 2 diabetes?

Its insulin effect is weaker. In a 1993 study, GIP's maximum insulin effect was 54% lower in mild type 2 diabetes than in matched controls.

Is tirzepatide the same as GIP?

No. Tirzepatide is a modified peptide based on the GIP sequence. It activates both the GIP and GLP-1 receptors and is an FDA-approved prescription medicine.

What to know now

  • GIP is a 42-amino-acid incretin hormone made by K cells in the small intestine.
  • It increases insulin when glucose is high and raises glucagon when glucose is low or normal.
  • In healthy men, blocking the GIP receptor reduced meal-related insulin secretion more than blocking the GLP-1 receptor.
  • Tirzepatide is based on the GIP sequence and activates both receptors; native GIP is not an approved medicine.

What we’re watching

  • Results of MARITIME-1 (NCT06858839), a Phase 3 trial of maridebart cafraglutide with 3,853 participants; primary completion is estimated for January 2027.
  • Research explaining why both GIP receptor activation and GIP receptor blocking are being studied for weight loss.
  • Regulatory decisions on retatrutide, which adds glucagon receptor activity to GIP and GLP-1 activity.

Also in the library

More for endocrine & metabolism

All 41 compounds for endocrine & metabolism

Sources: Brown 1971, Canadian Journal of Biochemistry, 49; Buffa 1975, Histochemistry, 43; Takeda 1987, Proceedings of the National Academy of Sciences of the United States of America, 84; Usdin 1993, Endocrinology, 133; Nauck 1993, Journal of Clinical Investigation, 91; Meier 2004a, Diabetes, 53; Meier 2004b, American Journal of Physiology. Endocrinology and Metabolism, 286; Christensen 2011, Diabetes, 60; Gasbjerg 2019, Diabetes, 68; Miyawaki 2002, Nature Medicine, 8; Coskun 2018, Molecular Metabolism, 18; Jastreboff 2025, New England Journal of Medicine, 393; Eli Lilly and Company 2026; Eli Lilly and Company 2026. All 14 citations

Back to the research library

References

  1. Brown, J. C., & Dryburgh, J. R. (1971). A gastric inhibitory polypeptide. II. The complete amino acid sequence. Canadian Journal of Biochemistry, 49(8), 867-872. https://pubmed.ncbi.nlm.nih.gov/5120249/
  2. Buffa, R., Polak, J. M., Pearse, A. G., Solcia, E., Grimelius, L., & Capella, C. (1975). Identification of the intestinal cell storing gastric inhibitory peptide. Histochemistry, 43(3), 249-255. https://pubmed.ncbi.nlm.nih.gov/1097380/
  3. Takeda, J., Seino, Y., Tanaka, K., Fukumoto, H., Kayano, T., Takahashi, H., et al. (1987). Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proceedings of the National Academy of Sciences of the United States of America, 84(20), 7005-7008. https://pubmed.ncbi.nlm.nih.gov/2890159/
  4. Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993). Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology, 133(6), 2861-2870. https://pubmed.ncbi.nlm.nih.gov/8243312/
  5. Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation, 91(1), 301-307. https://pubmed.ncbi.nlm.nih.gov/8423228/
  6. Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004a). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes, 53(3), 654-662. https://pubmed.ncbi.nlm.nih.gov/14988249/
  7. Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004b). Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. American Journal of Physiology. Endocrinology and Metabolism, 286(4), E621-E625. https://pubmed.ncbi.nlm.nih.gov/14678954/
  8. Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011). Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes, 60(12), 3103-3109. https://pubmed.ncbi.nlm.nih.gov/21984584/
  9. Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., et al. (2019). Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. Diabetes, 68(5), 906-917. https://pubmed.ncbi.nlm.nih.gov/30626611/
  10. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., et al. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine, 8(7), 738-742. https://pubmed.ncbi.nlm.nih.gov/12068290/
  11. Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14. https://pubmed.ncbi.nlm.nih.gov/30473097/
  12. Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., et al. (2025). Once-monthly maridebart cafraglutide for the treatment of obesity: A phase 2 trial. New England Journal of Medicine, 393(9), 843-857. https://pubmed.ncbi.nlm.nih.gov/40549887/
  13. Eli Lilly and Company. (2026). MOUNJARO (tirzepatide) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  14. Eli Lilly and Company. (2026). ZEPBOUND (tirzepatide) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b